Guardian Partners Inc. Acquires New Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Guardian Partners Inc. acquired a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,786,414 shares of the company’s stock, valued at approximately $5,413,000. Guardian Partners Inc. owned about 0.60% of AbCellera Biologics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in AbCellera Biologics in the 3rd quarter valued at about $668,000. JPMorgan Chase & Co. lifted its holdings in AbCellera Biologics by 6.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,747 shares of the company’s stock valued at $925,000 after purchasing an additional 21,483 shares in the last quarter. Moloney Securities Asset Management LLC purchased a new position in AbCellera Biologics in the 4th quarter valued at about $265,000. State Street Corp lifted its holdings in AbCellera Biologics by 1.5% in the 3rd quarter. State Street Corp now owns 323,229 shares of the company’s stock valued at $840,000 after purchasing an additional 4,679 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in AbCellera Biologics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company’s stock valued at $184,000 after purchasing an additional 5,955 shares in the last quarter. 61.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ABCL shares. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a report on Monday, March 3rd. KeyCorp reduced their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, Stifel Nicolaus cut their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 28th.

AbCellera Biologics Price Performance

Shares of ABCL stock opened at $2.44 on Friday. The firm has a market cap of $727.09 million, a P/E ratio of -4.00 and a beta of 0.45. AbCellera Biologics Inc. has a 1-year low of $2.11 and a 1-year high of $4.75. The firm’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $2.82.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.